A new study led by a University of Cincinnati researcher provides more clarity on how immunotherapy treatment for patients with cancer affects COVID-19 severity.
More than half of deaths that are not attributed to disease progression or recurrence after CAR T-cell therapy are caused by infections—an unprecedented finding that experts say marks a shift from a conventional focus on mitigating treatment-specific adverse events to including prevention and management of infections.
